Go to the list of all blogs
Allana's Avatar
published in Blogs
Jun 18, 2019
TickeronGET DAILY SIGNALS
Critical Retirement Questions You Should Answer

Critical Retirement Questions You Should Answer

Americans are Grossly Underprepared for Retirement. Are You?

Also in this newsletter

  • Healthcare sector ETF (XLV) trending lower since November

  • A.I. found two new patterns!

——————————————————————————————

Why You Need to Revisit Your Retirement Approach Now

Planning for retirement is not a one-size-fits-all process. It means evaluating myriad variables – post-retirement lifestyle, where to retire, cost of living, the rate of inflation, and more – then formulating a plan that considers current earnings and standard of living, in addition to… Read More…

——————————————————————————————

Healthcare sector ETF (XLV) trending lower since November

The overall market recovered from the selling that hit in December and that led the S&P 500 to a new all-time high on May 1. But not all stocks and sectors have recovered fully from the December selloff. One sector that has yet to recover fully is the healthcare sector… Read More…

——————————————————————————————

Current Trading Opportunity — Cup-and-Handle Inverse (Bearish)

——————————————————————————————

Current Trading Opportunity —Broadening Wedge Ascending (Bullish)

Related Ticker: XLV

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


XLV in upward trend: 10-day moving average broke above 50-day moving average on October 15, 2026

The 10-day moving average for XLV crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on XLV as a result. In 76 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.

The Moving Average Convergence Divergence (MACD) for XLV just turned positive on October 09, 2026. Looking at past instances where XLV's MACD turned positive, the stock continued to rise in 41 of 48 cases over the following month. The odds of a continued upward trend are 85%.

XLV moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +2.87% 3-day Advance, the price is estimated to grow further. Considering data from situations where XLV advanced for three days, in 263 of 325 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

The Aroon Indicator entered an Uptrend today. In 221 of 271 cases where XLV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XLV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

XLV broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Unitedhealth Group (NYSE:UNH), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Abbott Laboratories (NYSE:ABT), Pfizer (NYSE:PFE), Intuitive Surgical (NASDAQ:ISRG).

Industry description

The investment seeks investment results that, before expenses, correspond generally to the price and yield performance of publicly traded equity securities of companies in the Health Care Select Sector Index. In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.

Market Cap

The average market capitalization across the State Street Health Care Select Sector SPDR ETF (XLV) ETF is 115.63B. The market cap for tickers in the group ranges from 9.83B to 1.26T. LLY holds the highest valuation in this group at 1.26T. The lowest valued company is HSIC at 9.83B.

High and low price notable news

The average weekly price growth across all stocks in the State Street Health Care Select Sector SPDR ETF (XLV) ETF was 6%. For the same ETF, the average monthly price growth was 13%, and the average quarterly price growth was 33%. IDXX experienced the highest price growth at 24%, while ILMN experienced the biggest fall at -22%.

Volume

The average weekly volume growth across all stocks in the State Street Health Care Select Sector SPDR ETF (XLV) ETF was 42%. For the same stocks of the ETF, the average monthly volume growth was 33% and the average quarterly volume growth was 18%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 62
P/E Growth Rating: 47
Price Growth Rating: 25
SMR Rating: 59
Profit Risk Rating: 67
Seasonality Score: 30 (-100 ... +100)
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category Health

Category
Health
Address
One Lincoln Street Cph0326Boston
Phone
N/A
Web
www.spdrs.com
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
RBLX shares plunged approximately 24% in premarket trading on Friday, May 1, 2026, falling roughly $13.36 to around $41.90 from the prior close of approximately $55.26. The primary catalyst was a dramatic cut to full-year 2026 bookings guidance, slashed to $7.33B–$7.60B from $8.28B–$8.55B.
SMMT shares fell approximately 20% in premarket trading on Friday, May 1, 2026, dropping from a prior close of approximately $20.83 to around $16.66. The primary catalyst was the HARMONi-3 interim PFS analysis miss, with the Phase III global trial failing to meet expectations for its squamous cohort, undermining the ivonescimab thesis.